BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
- Conditions
- Healthy Participants
- Interventions
- Biological: BMS-986036Other: Placebo
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04649710
- Locations
- 🇰🇷
Local Institution, Busan, Korea, Republic of
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
- Conditions
- Moderate Liver ImpairmentSevere Liver Impairment
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT04634149
- Locations
- 🇺🇸
Local Institution - 0002, Miami, Florida, United States
🇺🇸Local Institution - 0001, San Antonio, Texas, United States
🇺🇸Local Institution, Orlando, Florida, United States
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 468
- Registration Number
- NCT04623775
- Locations
- 🇪🇸
Local Institution - 0048, Barcelona, Spain
🇪🇸Local Institution - 0061, Las Palmas, Spain
🇪🇸Local Institution - 0074, Madrid, Spain
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 38
- Registration Number
- NCT04613518
- Locations
- 🇺🇸
Local Institution - 0032, Garland, Texas, United States
🇦🇺Local Institution - 0005, Sydney, New South Wales, Australia
🇨🇦Local Institution - 0025, London, Ontario, Canada
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 41
- Registration Number
- NCT04572893
- Locations
- 🇺🇸
Local Institution - 0007, La Jolla, California, United States
🇺🇸Local Institution - 0010, Washington, District of Columbia, United States
🇺🇸Local Institution - 0009, Tampa, Florida, United States
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT04567667
- Locations
- 🇺🇸
Covance - Clinical Pharmacology Services - Madison, Madison, Wisconsin, United States
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Conditions
- Hepatocellular CarcinomaHepatomaLiver Cell Carcinoma, AdultLiver Cell CarcinomaLiver Cancer, Adult
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 266
- Registration Number
- NCT04567615
- Locations
- 🇧🇷
Local Institution - 0016, Barretos, SAO Paulo, Brazil
🇦🇷Local Institution - 0010, Ciudad de Buenos Aires, Buenos Aires, Argentina
🇦🇷Local Institution - 0019, Buenos Aires, Distrito Federal, Argentina
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT04550195
- Locations
- 🇳🇱
ICON Plc (PRA Health Sciences) - Netherlands, Groningen, Netherlands
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
- Conditions
- Melanoma
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 362
- Registration Number
- NCT04550247
- Locations
- 🇫🇷
Local Institution, Lille, France
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT04540705
- Locations
- 🇩🇪
Local Institution - 0044, Munich, Germany
🇺🇸Local Institution - 0001, Saint Louis, Missouri, United States
🇩🇪Local Institution - 0040, Jena, Germany